Keyphrases
Migraine
60%
Migraine Attack
43%
Migraine Treatment
42%
Headache
38%
Triptans
30%
Sumatriptan
26%
Calcitonin Gene-related Peptide
18%
Acute Treatment
16%
Antimigraine Drugs
16%
Cluster Headache
15%
Randomized Controlled Trial
13%
Placebo
11%
Tolerability
11%
Adverse Events
10%
Migraine Prevention
10%
Episodic Migraine
9%
Zolmitriptan
9%
Glyceryl Trinitrate
9%
Prophylactic Treatment
8%
Migraine Patients
8%
Migraine Drugs
8%
Headache Relief
7%
Lasmiditan
7%
Blood-brain Barrier
7%
Migraine without Aura (MWoA)
7%
Telcagepant
7%
Efficacy Index
7%
Acute Migraine
7%
Calcitonin Receptor
7%
Erenumab
6%
Aspirin
6%
Placebo-controlled
6%
Verapamil
6%
Naratriptan
6%
Cortical Spreading Depression
6%
Migraine Headache
5%
Monoclonal Antibody
5%
Drug Treatment
5%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5%
Pharmacokinetics
5%
Headache Attacks
5%
International Headache Society
5%
Neurology
5%
Nitroglycerin
5%
Clinical Pharmacology
5%
Pharmacokinetic Variability
5%
Rizatriptan
5%
Pharmacology, Toxicology and Pharmaceutical Science
Migraine
100%
Headache
26%
Triptan Derivative
22%
Sumatriptan
22%
Placebo
15%
Cluster Headache
13%
Randomized Controlled Trial
13%
Calcitonin Gene Related Peptide Receptor Antagonist
13%
Pharmacokinetics
12%
Tolerability
11%
Calcitonin Gene Related Peptide
10%
Zolmitriptan
9%
Adverse Event
8%
Glyceryl Trinitrate
8%
Normal Human
8%
Telcagepant
7%
Lasmiditan
7%
Blood-Brain Barrier
6%
Verapamil
6%
Naratriptan
6%
Episodic Migraine
5%
Non-Steroidal Anti-Inflammatory Drug
5%
Pharmacotherapy
5%
Receptor Agonist
5%
Pharmacodynamics
5%
Acetylsalicylic Acid
5%
Erenumab
5%
Clinical Pharmacology
5%
Monoclonal Antibody
5%